000			03891nam a22003735i 4500
001			106818
003			ESmaUEC
005			20230102113315.0
006			a||||fo|||| 00| 0
007			cr nn nnnaamaa
008			190108s2018 gw | s |||| 0|eng d
020			_a9783030027711 _9
024	7		_a10.1007/978-3-030-02771-1 _2doi
040			_aES-MaUEC _bspa _cES-MaUEC
050		4	_aRC280.C6 _b2018 EB
245	0	0	_aTargeted Therapy of Colorectal Cancer Subtypes _cedited by Peter Jordan
264		1	_aCham _bSpringer International Publishing _c2018
300			_a1 recurso en línea (VIII, 150 páginas) _b9 ilustraciones a color
336			_aTexto _btxt _2rdacontent
347			_atext file _bPDF _2rda
490	0		_aAdvances in Experimental Medicine and Biology _x0065-2598 _v1110
505	0		_aPreface -- Colorectal Cancer Subtypes- the current portrait -- Targeting colon cancers with mutated BRAF and microsatellite instability -- Targeting KRAS mutant CMS3 subtype by metabolic inhibitors -- Targeting the PI3K Signalling as a Therapeutic Strategy in Colorectal Cancer -- Targeting PTEN in colorectal cancers -- Wnt signalling-targeted therapy in the CMS2 tumour subtype: a new paradigm in CRC treatment?- Impact of the microenvironment on tumour budding in colorectal cancer -- Anti-EGFR Therapy to treat metastatic colorectal cancer: not for all -- miRNAs as modulators of EGFR therapy in colorectal cancer -- Index.
520	3		_aIn this book, a group of researchers shares their expertise on the identification and characterization of genetic colorectal cancer subtypes. They describe solid pathobiological knowledge on the distinct sporadic tumour subtypes, including the mutations found in oncogenes and tumour suppressor genes, the types of genomic instability encountered, and the cellular signalling pathways activated. The book content indicates opportunities for the development of further pathway-specific therapeutic drugs or drug combinations, allowing to cope with the appearance of resistant tumours. The nine chapters of this book cover the main aspects underlying colorectal cancer development but also of its therapeutic options, which have been undergoing substantial changes by moving from the use of general cytotoxic agents that affect rapidly growing cells to more tumour-specific drugs. In the first case, all dividing cells in the patient's body are affected and this causes severe and debilitating side effects. In the second case, the increasing knowledge about the molecular genetics of tumours has led to a new generation of drugs, which specifically interfere with the cell survival pathways that are activated in a given tumour. This allowed to identify groups of patients for targeted therapy that is much better tolerated. The book is thus an interesting update for health professionals on the current knowledge on heterogeneity in colorectal cancer. In addition, it should inspire the drug-developing scientific community by highlighting potential therapeutic Achilles heels of distinct subtypes of colorectal cancer.
650		7	_aColon _xCáncer _9182269 _2embne
700	1		_aJordan, Peter _eeditor literario _4edt _4http://id.loc.gov/vocabulary/relators/edt _0http://id.loc.gov/authorities/names/n83329948 _1http://viaf.org/viaf/279151271
710	2		_aSpringerLink (Online service) _0http://id.loc.gov/authorities/names/no2005046756 _1http://viaf.org/viaf/148105729 _9106996
776	0	8	_iPrinted edition: _z9783030027704
776	0	8	_iPrinted edition: _z9783030027728
856	4	0	_uhttps://go.openathens.net/redirector/universidadeuropea.es?url=https://doi.org/10.1007/978-3-030-02771-1 _zAcceso a este recurso digital (usuarios Universidad Europea de Madrid)
490	0		_aBiomedical and Life Sciences (Springer-11642)
942			_2lcc
988			_aEBSPRINGER_BIOMEDLIFE_2019
998			_aSI _a_alco _a_vill _b01/2019 _cm _dz _ef _feng _ggw _h0
999			_c106818 _d106818 _x1